1. Home
  2. EXG vs SUPN Comparison

EXG vs SUPN Comparison

Compare EXG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXG
  • SUPN
  • Stock Information
  • Founded
  • EXG 2007
  • SUPN 2005
  • Country
  • EXG United States
  • SUPN United States
  • Employees
  • EXG N/A
  • SUPN N/A
  • Industry
  • EXG Finance Companies
  • SUPN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXG Finance
  • SUPN Health Care
  • Exchange
  • EXG Nasdaq
  • SUPN Nasdaq
  • Market Cap
  • EXG 2.7B
  • SUPN 2.6B
  • IPO Year
  • EXG N/A
  • SUPN 2012
  • Fundamental
  • Price
  • EXG $9.21
  • SUPN $47.92
  • Analyst Decision
  • EXG
  • SUPN Buy
  • Analyst Count
  • EXG 0
  • SUPN 2
  • Target Price
  • EXG N/A
  • SUPN $51.50
  • AVG Volume (30 Days)
  • EXG 533.2K
  • SUPN 682.2K
  • Earning Date
  • EXG 01-01-0001
  • SUPN 11-03-2025
  • Dividend Yield
  • EXG 8.27%
  • SUPN N/A
  • EPS Growth
  • EXG N/A
  • SUPN 1411.53
  • EPS
  • EXG N/A
  • SUPN 1.14
  • Revenue
  • EXG N/A
  • SUPN $665,125,000.00
  • Revenue This Year
  • EXG N/A
  • SUPN $6.71
  • Revenue Next Year
  • EXG N/A
  • SUPN $19.74
  • P/E Ratio
  • EXG N/A
  • SUPN $42.23
  • Revenue Growth
  • EXG N/A
  • SUPN 5.55
  • 52 Week Low
  • EXG $6.78
  • SUPN $29.16
  • 52 Week High
  • EXG $8.15
  • SUPN $49.66
  • Technical
  • Relative Strength Index (RSI)
  • EXG 69.54
  • SUPN 66.02
  • Support Level
  • EXG $9.12
  • SUPN $47.34
  • Resistance Level
  • EXG $8.97
  • SUPN $49.66
  • Average True Range (ATR)
  • EXG 0.08
  • SUPN 1.23
  • MACD
  • EXG 0.02
  • SUPN -0.08
  • Stochastic Oscillator
  • EXG 88.00
  • SUPN 66.70

About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: